Fidelio acquires Indical Bioscience

April 5, 2018

Fidelio acquires Indical Bioscience, a leading provider of diagnostic products specifically developed for veterinary specific applications.

The company develops and markets diagnostic solutions and products based on PCR (molecular) and ELISA (immunodiagnostic) technology. The products are used by laboratories primarily to indicate and diagnose viruses and bacteria in production animals, to counteract proliferation and contribute to better animal and human health.

Indical Bioscience is based in Germany and serves customers in 169 countries through its own sales force and commercial partners. Fidelio Capital acquired Indical Bioscience through a carve-out from Qiagen, a molecular diagnostic group listed on the NYSE and Frankfurt stock exchanges.

Recent news

iBinder acquires REQS System

iBinder Group acquires REQS System AB and strengthens the group’s offering in property management, inspections, and controlling. The acquisition is an important step in iBinder’s goal of creating a simple platform for the property’s entire life cycle – from idea

Read more

Odevo continues US expansion as Spectrum AM joins…

Odevo, an international leader that is driving change in the traditional property management industry, continues its rapid expansion in the US market with the addition of successful Texas-based Spectrum Association Management and five additional new brands joining the Group. These

Read more

iBinder expands outside the Nordics

Swedish Software as a Service company iBinder develops and provides the construction and real estate industries with digital solutions for efficient collaboration. The company’s core solution is a cloud-based collaboration platform that ensures efficient and easy sharing of information throughout

Read more